Synthesis, antineoplastic and cytotoxic activities of some mononuclear Ru(II) complexes

References

• Clarke MJ, Zhu F, Frasca DR. Non-platinum chemotherapeutic metallo pharmaceuticals. Chem Rev 1999;99:2511–34.
   PubMed Web of Science ®Google Scholar
• Kureshy RI, Khan NH. Mononuclear chiral ruthenium(II) Schiff base complexes; synthesis, physicochemical studies and reactivity with π-acceptor ligands. Polyhedron 1999;12:195–201.
   Web of Science ®Google Scholar
• Chakravarty J, Bhattacharya S. Ruthenium phenolates, synthesis, characterization and electron-transfer properties of some salylaldiminato and 2-(arylazo) phenolates complexes of ruthenium. Polyhedron 1996;15:1047–55.
   Web of Science ®Google Scholar
• Baitalik S, Adhikary B. Heterochelates of ruthenium(II): electrochemistry, absorption spectra, and luminescence properties. Polyhedron 1997;16:4073–80.
   Web of Science ®Google Scholar
• Clarke MJ. Ruthenium metallo pharmaceuticals. Coord Chem Rev 2003;236:209–33.
   Web of Science ®Google Scholar
• Clarke MJ. Oncological implications of the chemistry of ruthenium. Met Ions Biol Syst 1980;11:231–83.
   Google Scholar
• Rudolph R. Electron microscopy demonstration of sulphurated acid monopolysaccarides in canine mast cell tumours, using barium chloride and ruthenium red, together with comments on the classification and differentiation of tumor cells. Arch Exp Veterinarmed 1971;25:925–35.
   PubMedGoogle Scholar
• Anghileri LJ, Krebsforsch Z. The in vivo inhibition of tumor growth by ruthenium red: its relationship with the metabolism of calcium in the tumor. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 1975;83:213–17.
   PubMedGoogle Scholar
• Keppler BK, Henn M, Juhl UM, Berger MR, Niebi R, Wagner FE. New ruthenium complexes for the treatment of cancer. Prog Clin Biochem Med 1989;10:41–69.
   Google Scholar
• Novakova O, Kasparkova J, Vrana O, Van Vilet PM, Reedijk J, Brabec V. Correlation between cytotoxicty and DNA binding polypyridyl ruthenium complexes. Biochemistry 1995;34:12369–78.
   PubMed Web of Science ®Google Scholar
• Vilaplana RA, Gonazalez-Vichez F, Gutierrez-Puebla E, Ruiz-Valero C. The first isolated antineoplatic Ru(IV) complex; synthesis and structure of [Cl2 [1,2-cyclohexane diaminotetra acetate) Ru] 2H2O. Inorg Chim Acta 1994;224:15–18.
   Web of Science ®Google Scholar
• Sava G, Bergamo A, Zorzet S, Gava B, Casarsa C. Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A. Eur J Cancer 2002;38:427–35.
   PubMed Web of Science ®Google Scholar
• Keppler BK, Wehe D, Enders H, Rupp W. Syntheisis, antitumor activity, and X-ray structure of bis (imidazolium) imidazole-pentachloro ruthenate (III), (ImH)2 (RuImCl5). Inorg Chem 1987;26:844–6.
   Web of Science ®Google Scholar
• Keppler BK, Rupp W, Juhl UM, Endres H, Nieu R, Blazer WS. Synthesis, molecular structure and tumor-inhibiting property of imidazolium-trans-bis(imidazole) tetra chlororuthenate (III) and its methyl substituted derivatives. Inorg Chem 1987;26:4366–70.
   Web of Science ®Google Scholar
• Sava G, Gangliyardi R, Bergamo A, Alessio E, Mestroni G. Treatment of metastases of solid mouse tumors by NAMI-A; comparison with cisplatin, cyclophosphamide and decarbazine. Anticancer Res 1999;19:969–72.
   PubMed Web of Science ®Google Scholar
• Velders AH, Pazderski L, Ugozzoli F, Biagini-Cingi M, Reedijk J. Synthesis, characterization and crystal structure of trans-aquatrichlorobis (5,7-dimethyl 1,2,4 triazolo 1,5-a pyrimidine-N3) ruthenium (III) monohydrate. Inorg Chim Acta 1998;273:259–65.
   Web of Science ®Google Scholar
• Velders AH, Ugozzoli F, Biagini-Cingi M, Reedijk JJ. A unique fourfold intramolecular hydrogen bonding stabilizes the structure of trans-bis (2-amino-5,7-dimethyl [1,2,4] triazolo [1,5-a] pyrimidine-N3) aquatrichloro ruthenium (III) monohydrate. Eur J Inorg Chem 1999;273:213–15.
   Google Scholar
• Sava G, Bergamo A. Ruthenium-based compounds and tumor growth control. Int J Oncol 2000;17:353–65.
   PubMed Web of Science ®Google Scholar
• Rademaker-Lakhai JM, Bongard DV, Pluim D, Beijnen JH. A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin Cancer Res 2004;10:3717–27.
   PubMed Web of Science ®Google Scholar
• Gagliardi R, Sava G, Pacor S, Mestroni G, Alessio E. Antimetastatic action and toxicity on healthy tissues of Na [trans-RuCl4 (DMSO) Im] in the mouse. Clin Exp Metastasis 1994;12:93–100.
   PubMed Web of Science ®Google Scholar
• Maganarin M, Bergamo A, Carotenuto ME, Zorzet S, Sava G. Increase of tumor infiltrating lymphocytes in mice treated with antimetastatic doses of NAMI-A. Anticancer Res 2000;20:2939–44.
   PubMed Web of Science ®Google Scholar
• Cocchietto M, Sava G. Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in mice. Pharmacol Toxicol 2000;87:193–7.
   PubMedGoogle Scholar
• Zorzet S, Sorc A, Casarsa C, Cocchietto M, Sava G. Pharmacological effects of the ruthenium complex NAMI-A given orally to CBA mice with MCa mammary carcinoma. Met Based Drugs 2001;8:1–7.
   PubMedGoogle Scholar
• Sava G, Clerici K, Capozzi I, Cocchietto M, Gagliardi R, Alessio. E, et al. Reduction of lung metastasis by ImH (trans-RuCl4 (DMSO) Im: mechanism of the selective action investigated on mouse tumors. Anticancer Drugs 1999;10:129–38.
   PubMed Web of Science ®Google Scholar
• Sava G, Gagliardi R, Cocchietto M, Clerici K, Capozzi I, Marella M, et al. Comparison of the effects of the antimetastatic compound ImH (trans-RuCl4 (DMSO) (Im)] (NAMI-A) on the arthritic rat and on MCa mammary carcinoma in mice. Pathol Oncol Res 1998;4:30–6.
   PubMedGoogle Scholar
• Keppler BK, Henn M, Juhl UM, Berger MR, Niebel R, Wagner FE. New ruthenium complexes for the treatment of cancer. Prog Clin Biochem Med 1989;10:41–69.
   Google Scholar
• Kreuser ED, Keppler BK, Berdel WE, Piest A, Thiel E. Synergistic antitumor interactions between newly synthesized ruthenium complexes and cytokines in human colon carcinoma cell lines. Semin Oncol 1992;19:73–81.
   PubMed Web of Science ®Google Scholar
• Sava G, Pacor S, Zorzet S, Alessio E, Mestroni G. Antitumor properties of dimethyl sulphoxide ruthenium (II) complexes in the Lewis lung carcinoma system. Pharmacol Res 1989;21:617–28.
   PubMed Web of Science ®Google Scholar
• Zorzet S, Bergamo A, Cocchietto M, Sorc A, Gava B, Alessio E, et al. Lack of in vitro cytotoxicity, associated to increased G2-M cell fraction and inhibition of matrigel invasion, may predict in vivo selective antimetastasis activity of ruthenium complexes. Pharmacol Exp Ther 2000;295:927–33.
   PubMed Web of Science ®Google Scholar
• Clarke MJ, Galang RD, Roudriguez VM, Kumar R, Pell S, Bryan DM. Chemical considerations in the design of ruthenium anticancer agents. In: Nicolini M, ed. Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Boston, MA: Martinus Nijhoff, 1988:582–601.
   Google Scholar
• Tysoe SA, Morgan RJ, Baker D. Spectroscopic investigation of differential binding modes of δ- and λ- Ru (bpy)2 (ppz)2+ with calf thymus DNA. J Phys Chem 1993;97:1707–11.
   Web of Science ®Google Scholar
• Clairs SA, Paul JD. Ruthenium in medicine: current clinical uses and future prospects. Platinum Met Rev 2001;45:62–9.
   Web of Science ®Google Scholar
• Mazumder UK, Gupta M., Bera A, Bhattacharya S, Karki S, Manikadan L, et al. Synthesis, antitumor and antibacterial activity of some Ru(bpy)22+/4-substituted thiosemicarbazide complexes. Indian J Chem 2003;42A:313–17.
   Google Scholar
• Mazumder UK, Gupta M, Karki S, Bhattacharya S, Suresh R, Sivakumar T. Synthesis, and pharmacological activities of some mononuclear Ru(II) complexes. Bioorg Med Chem 2005;13:5766–73.
   PubMed Web of Science ®Google Scholar
• Suresh R, Karki SS, Bhattacharya S, Manikadan L, Prabhakaran SG, Mazumder UK, et al. Synthesis, and anticancer activity of certain mononuclear Ru(II) complexes. J Enzyme Inhib Med Chem 2006;21:501–7.
   PubMed Web of Science ®Google Scholar
• Karki SS, Sreekanth T, Balzarini J, Clercq DE. Synthesis, anticancer and cytotoxic activities of some mononuclear Ru(II) compounds. Bioorg Med Chem 2007;15:6632–41.
   PubMed Web of Science ®Google Scholar
• Giordano PJ, Bock CR, Wrighton MS. Excited state proton transfer of ruthenium(II) complexes of 4, 7-dihydroxy-1,10-phenanthroline. Increased acidity in the excited state. J Am Chem Soc 1978;100:6960–6.
   Web of Science ®Google Scholar
• Litchfield JT, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 1949;96:99–113.
   PubMed Web of Science ®Google Scholar
• Balzarini J, De Clercq E, Mertes MP, Shugar D, Torrence PF. 5-Substituted 2′-deoxy uridines: correlation between inhibition of tumor cell growth and inhibition of thymidine kinase and thymidylate synthetase. Biochem Pharmacol 1982;31:3673–82.
   PubMed Web of Science ®Google Scholar
• Nardelli M, Gasparri GF, Battislini GG, Musatti A. Configuration of thiosemicarbazide molecules in monochloro monothiosemicarbazide silver. Chem Commun 1965:187–188.
   Google Scholar
• Gasparri GF, Mangia A, Musatti A, Nardelli M. The crystal and molecular structure of monothiosemicarbazide silver(I) chloride. Acta Crystallogr 1968;24:367–74.
   Web of Science ®Google Scholar